Vnitr Lek 2021, 67(1):7-14 | DOI: 10.36290/vnl.2021.001

What internist can do for the patient after the ischemic stroke

Miroslav Škorňa
Neurologická klinika LF MU a FN Brno

Stroke is frequent disease especially in older age. It is complex multidisciplinary issue and the internist plays very important role in the care of the stroke patients. Recurrent stroke is often disabling. Therefor the early and proper implementation of the effective secondary prevention is essential. This review presents basic information about the aetiology, diagnostic assessment and the secondary prevention of the ischemic stroke.

Keywords: troke, aetiology, secondary prevention.

Published: March 2, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Škorňa M. What internist can do for the patient after the ischemic stroke. Vnitr Lek. 2021;67(1):7-14. doi: 10.36290/vnl.2021.001.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ, Culebras A et al. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013; 44(7): 2064-2089. Go to original source... Go to PubMed...
    2. Škoda O, Herzig R, Mikulík R, Neumann J, Václavík D, Bar M et al. Klinický standard pro diagnostiku a léčbu pacientů s ischemickou cévní mozkovou příhodou a s tranzitorní ischemickou atakou - verze 2016. Cesk Slov Neurol N. 2016; 79/112(3): 351-363. Go to original source...
    3. Škorňa M, Neumann J, Peška S, Mikulík R. Management tranzitorní ischemické ataky a minor stroke. Cesk Slov Neurol N. 2016; 79/112(2): 178-187. Go to original source...
    4. Coupland AP, Thapar A, Qureshi MI, Jenkins H, Davies AH. The definition of stroke. JR Soc Med. 2017; 110(1): 9-12. Go to original source... Go to PubMed...
    5. Easton JD, Saver JL, Albers GW, Alberts MJ, Chaturvedi S, Feldmann E et al. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke. 2009; 40(6): 2276-2293. Go to original source... Go to PubMed...
    6. Sedova P, Brown RD, Zvolsky M, Kadlecova P, Bryndziar T, Kubelka T et al. Incidence of Hospitalized Stroke in the Czech Republic: The National Registry of Hospitalized Patients. J Stroke Cerebrovasc, DiS. 2017; 26(5): 979-986. Go to original source... Go to PubMed...
    7. Bruthans J. Epidemiologie a prognóza cévních mozkových příhod. 2009; 19(2).
    8. Coutts SB, Modi J, Patel SK, Aram H, Demchuk AM, Goyal M et al. What causes disability after transient ischemic attack and minor stroke?: Results from the CT and MRI in the Triage of TIA and minor Cerebrovascular Events to Identify High Risk Patients (CATCH) Study. Stroke. 2012; 43(11): 3018-3022. Go to original source... Go to PubMed...
    9. Ay H, Furie KL, Singhal A, Smith WS, Sorensen AG, Koroshetz WJ. An evidence‑based causative classification system for acute ischemic stroke. Ann Neurol. 2005; 58(5): 688-697. Go to original source... Go to PubMed...
    10. Tomek A. Základní algoritmus vyšetření etiologie ischemické cévní mozkové příhody. Neurol praxi. 2019; 20(1): 12-16. Go to original source...
    11. Sposato LA, Cipriano LE, Saposnik G, Ruíz Vargas E, Riccio PM, Hachinski V. Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta‑analysis. Lancet Neurol. 2015; 14(4): 377-387. Go to original source... Go to PubMed...
    12. Kimura K, Minematsu K, Yamaguchi T, (J‑MUSIC) JMSIC. Atrial fibrillation as a predictive factor for severe stroke and early death in 15,831 patients with acute ischaemic stroke. J Neurol Neurosurg Psychiatry. 2005; 76(5): 679-683. Go to original source... Go to PubMed...
    13. Nouh A, Hussain M, Mehta T, Yaghi S. Embolic Strokes of Unknown Source and Cryptogenic Stroke: Implications in Clinical Practice. Front Neurol. 2016; 7: 37. Go to original source... Go to PubMed...
    14. Šaňák D, Hutyra M, Král M, Špaček M, Bártková A. Soumrak kryptogenní ischemické CMP - kardioembolizace je nejčastější příčina. Cesk Slov Neurol N. 2018; 81/114(3): 290-297. Go to original source...
    15. Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O'Donnell MJ et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014; 13(4): 429-438. Go to original source... Go to PubMed...
    16. Hart RG, Catanese L, Perera KS, Ntaios G, Connolly SJ. Embolic Stroke of Undetermined Source: A Systematic Review and Clinical Update. Stroke. 2017; 48(4): 867-72. Go to original source... Go to PubMed...
    17. Tomek A, Olšerová A. Embolický iktus z neurčeného zdroje. Neurol praxi. 2019; 20(1): 28-32. Go to original source...
    18. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström‑Lundqvist C et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio‑Thoracic Surgery (EACTS). Eur Heart J. 2020.
    19. Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med. 2014; 370(26): 2467-2477. Go to original source... Go to PubMed...
    20. Wachter R, Gröschel K, Gelbrich G, Hamann GF, Kermer P, Liman J et al. Holter‑electrocardiogram‑monitoring in patients with acute ischaemic stroke (Find‑AF. Lancet Neurol. 2017; 16(4): 282-290. Go to original source... Go to PubMed...
    21. Brachmann J, Morillo CA, Sanna T, Di Lazzaro V, Diener HC, Bernstein RA, et al. Uncovering Atrial Fibrillation Beyond Short‑Term Monitoring in Cryptogenic Stroke Patients: Three‑Year Results From the Cryptogenic Stroke and Underlying Atrial Fibrillation Trial. Circ Arrhythm Electrophysiol. 2016; 9(1): e003333. Go to original source... Go to PubMed...
    22. Šaňák D, Tomek A, Bar M, Herzig R, Mikulík R, Neumann J et al. Stanovisko Výboru Cerebrovaskulární sekce České neurologické společnosti ČLS JEP k dlouhodobému holterovskému EKG monitoringu u pacientů s ischemickou cévní mozkovou příhodou. Cesk Slov Neurol N. 2018; 81/114(5): 607.
    23. Ricci B, Chang AD, Hemendinger M, Dakay K, Cutting S, Burton T, et al. A Simple Score That Predicts Paroxysmal Atrial Fibrillation on Outpatient Cardiac Monitoring after Embolic Stroke of Unknown Source. J Stroke Cerebrovasc, DiS. 2018; 27(6): 1692-1696. Go to original source... Go to PubMed...
    24. Li YG, Bisson A, Bodin A, Herbert J, Grammatico‑Guillon L, Joung B, et al. C 2 HEST Score and Prediction of Incident Atrial Fibrillation in Poststroke Patients: A French Nationwide Study. J Am Heart Assoc. 2019; 8(13): e012546. Go to original source... Go to PubMed...
    25. Germain DP. Fabry disease. Orphanet J Rare, DiS. 2010; 5: 30. Go to original source... Go to PubMed...
    26. Namdar M. Electrocardiographic Changes and Arrhythmia in Fabry Disease. Front Cardiovasc Med. 2016; 3: 7. Go to original source... Go to PubMed...
    27. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014; 45(7): 2160-2236. Go to original source... Go to PubMed...
    28. Magerová H. Indikace antitrombotické terapie v sekundární prevenci ischemické CMP. Neurol praxi. 2019; 20(1): 17-20. Go to original source...
    29. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non‑vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018; 39(16): 1330-1393. Go to original source... Go to PubMed...
    30. Saposnik G, Barinagarrementeria F, Brown RD, Bushnell CD, Cucchiara B, Cushman M, et al. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011; 42(4): 1158-1192. Go to original source... Go to PubMed...
    31. Ntaios G, Papavasileiou V, Diener HC, Makaritsis K, Michel P. Nonvitamin‑K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: An updated systematic review and meta‑analysis of randomized controlled trials. Int J Stroke. 2017; 12(6): 589-596. Go to original source... Go to PubMed...
    32. Diener HC, Aisenberg J, Ansell J, Atar D, Breithardt G, Eikelboom J et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non‑valvular atrial fibrillation: part 1. Eur Heart J. 2017; 38(12): 852-859. Go to original source... Go to PubMed...
    33. Diener HC, Aisenberg J, Ansell J, Atar D, Breithardt G, Eikelboom J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non‑valvular atrial fibrillation: part 2. Eur Heart J. 2017; 38(12): 860-868. Go to original source... Go to PubMed...
    34. Osmancik P, Herman D, Neuzil P, Hala P, Taborsky M, Kala P, et al. Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High‑Risk Patients With Atrial Fibrillation. J Am Coll Cardiol. 2020; 75(25): 3122-3135. Go to original source... Go to PubMed...
    35. Mas JL, Derumeaux G, Guillon B, Massardier E, Hosseini H, Mechtouff L, et al. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke. N Engl J Med. 2017; 377(11): 1011-1021. Go to original source... Go to PubMed...
    36. Derdeyn CP, Chimowitz MI, Lynn MJ, Fiorella D, Turan TN, Janis LS et al. Aggressive medical treatment with or without stenting in high‑risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. Lancet. 2013. Go to original source...
    37. Wang Y, Johnston SC. Clopidogrel with aspirin in minor stroke or transient ischemic attack. N Engl J Med. 2013; 369(14): 1376-1377. Go to original source... Go to PubMed...
    38. Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ et al. Clopidogrel and Aspirin in Acute Ischemic Stroke and High‑Risk TIA. N Engl J Med. 2018; 379(3): 215-225. Go to original source... Go to PubMed...
    39. Johnston SC, Amarenco P, Denison H, Evans SR, Himmelmann A, James S et al. Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. N Engl J Med. 2020; 383(3): 207-217. Go to original source... Go to PubMed...
    40. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. New England Journal of Medicine. 2017; 377(14): 1319-1330. Go to original source... Go to PubMed...
    41. Sharma M, Hart RG, Connolly SJ, Bosch J, Shestakovska O, Ng KKH et al. Stroke Outcomes in the COMPASS Trial. Circulation. 2019; 139(9): 1134-1145. Go to original source... Go to PubMed...
    42. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001; 345(20): 1444-1451. Go to original source... Go to PubMed...
    43. Longstreth WT, Jr., Kronmal RA, Thompson JL, Christenson RH, Levine SR, Gross R et al. Amino terminal pro‑B-type natriuretic peptide, secondary stroke prevention, and choice of antithrombotic therapy. Stroke. 2013; 44(3): 714-719.
    44. Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD et al. Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. N Engl J Med. 2018; 378(23): 2191-201. Go to original source... Go to PubMed...
    45. Diener HC, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchiyama S et al. Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. N Engl J Med. 2019; 380(20): 1906-1917. Go to original source... Go to PubMed...
    46. Healey JS, Gladstone DJ, Swaminathan B, Eckstein J, Mundl H, Epstein AE et al. Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation: Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial. JAMA Neurol. 2019; 76(7): 764-773. Go to original source... Go to PubMed...
    47. Kamel H, Longstreth WT, Jr., Tirschwell DL, Kronmal RA, Broderick JP, Palesch YY et al. The AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke randomized trial: Rationale and methods. Int J Stroke. 2019; 14(2): 207-214. Go to original source... Go to PubMed...
    48. Geisler T, Poli S, Meisner C, Schreieck J, Zuern CS, Nägele T et al. Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design. Int J Stroke. 2017; 12(9): 985-990.Další literatura u autoraa na www.casopisvnitrnilekarstvi.cz Go to original source... Go to PubMed...
    49. Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc. 1984; 59(1): 17-20. Go to original source... Go to PubMed...
    50. Søndergaard L, Kasner SE, Rhodes JF, Andersen G, Iversen HK, Nielsen‑Kudsk JE et al. Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke. N Engl J Med. 2017;377(11): 1033-1042. Go to original source... Go to PubMed...
    51. Saver JL, Carroll JD, Thaler DE, Smalling RW, MacDonald LA, Marks DS et al. Long‑Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke. N Engl J Med. 2017; 377(11): 1022-1032. Go to original source... Go to PubMed...
    52. Šrámek M. Kdy uzavírat perzistující foramen ovale? Neurol praxi. 2019; 20(1): 25-27. Go to original source...
    53. Kent DM, Ruthazer R, Weimar C, Mas JL, Serena J, Homma S et al. An index to identify stroke‑related vs incidental patent foramen ovale in cryptogenic stroke. Neurology. 2013; 81(7): 619-625. Go to original source... Go to PubMed...
    54. Holmes DR, Jr., Doshi SK, Kar S, Price MJ, Sanchez JM, Sievert H et al. Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient‑Level Meta‑Analysis. J Am Coll Cardiol. 2015; 65(24): 2614-2623. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.